SAMSUNG PHARM. Co., LTD. (KRX:001360)
South Korea · Delayed Price · Currency is KRW 1,723.00
-45.00 (-2.55%)
May 15, 2026, 11:50 AM KST
SAMSUNG PHARM. Co., LTD. Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
Operating Revenue | 44,294 | 51,955 | 46,484 | 41,919 | 47,194 |
Other Revenue | - | - | - | - | 0 |
| 44,294 | 51,955 | 46,484 | 41,919 | 47,194 | |
Revenue Growth (YoY) | -14.74% | 11.77% | 10.89% | -11.18% | 11.93% |
Cost of Revenue | - | - | 37,903 | 36,851 | 38,425 |
Gross Profit | 44,294 | 51,955 | 8,580 | 5,069 | 8,770 |
Selling, General & Admin | - | - | 12,228 | 11,708 | 15,001 |
Research & Development | - | - | 377.51 | 938.79 | 898.61 |
Amortization of Goodwill & Intangibles | - | - | 18.92 | 246.65 | 1,034 |
Other Operating Expenses | 29,465 | 33,918 | 755.65 | 261.64 | 475.91 |
Operating Expenses | 29,465 | 33,918 | 13,980 | 12,843 | 15,096 |
Operating Income | 14,829 | 18,037 | -5,399 | -7,774 | -6,327 |
Interest Expense | - | - | -1,357 | -2,590 | -2,456 |
Interest & Investment Income | - | - | 1,246 | 692.21 | 323.74 |
Currency Exchange Gain (Loss) | - | - | -9.87 | -26.54 | 45.02 |
Other Non Operating Income (Expenses) | -2,117 | 5,638 | 273.82 | -870.64 | -1,665 |
EBT Excluding Unusual Items | 12,711 | 23,675 | -5,246 | -10,569 | -10,079 |
Gain (Loss) on Sale of Investments | - | - | 3,203 | -117.01 | -3,605 |
Gain (Loss) on Sale of Assets | - | - | 27 | 292.49 | 13.04 |
Asset Writedown | - | - | - | -577.53 | -3,067 |
Other Unusual Items | - | - | - | 5.46 | -609.29 |
Pretax Income | 12,711 | 23,675 | -2,016 | -10,966 | -17,348 |
Income Tax Expense | - | -1,137 | 59.55 | -3,692 | -129.71 |
Earnings From Continuing Operations | 12,711 | 24,812 | -2,076 | -7,274 | -17,218 |
Earnings From Discontinued Operations | - | - | - | -265.93 | -4,400 |
Net Income to Company | 12,711 | 24,812 | -2,076 | -7,540 | -21,618 |
Minority Interest in Earnings | - | - | - | -0 | 0 |
Net Income | 12,711 | 24,812 | -2,076 | -7,540 | -21,618 |
Net Income to Common | 12,711 | 24,812 | -2,076 | -7,540 | -21,618 |
Net Income Growth | -48.77% | - | - | - | - |
Shares Outstanding (Basic) | - | - | 51 | 40 | 33 |
Shares Outstanding (Diluted) | - | - | 51 | 40 | 33 |
Shares Change (YoY) | - | - | 28.44% | 21.80% | 28.46% |
EPS (Basic) | - | - | -40.51 | -189.00 | -660.00 |
EPS (Diluted) | - | - | -40.51 | -189.00 | -660.00 |
Free Cash Flow | - | - | -9,134 | -956.01 | -43,177 |
Free Cash Flow Per Share | - | - | -178.27 | -23.96 | -1318.23 |
Gross Margin | 100.00% | 100.00% | 18.46% | 12.09% | 18.58% |
Operating Margin | 33.48% | 34.72% | -11.62% | -18.55% | -13.41% |
Profit Margin | 28.70% | 47.76% | -4.46% | -17.99% | -45.80% |
Free Cash Flow Margin | - | - | -19.65% | -2.28% | -91.49% |
EBITDA | - | - | -1,635 | -3,859 | -2,060 |
EBITDA Margin | - | - | -3.52% | -9.21% | -4.37% |
D&A For EBITDA | - | - | 3,764 | 3,915 | 4,267 |
EBIT | 14,829 | 18,037 | -5,399 | -7,774 | -6,327 |
EBIT Margin | 33.48% | 34.72% | -11.62% | -18.55% | -13.41% |
Advertising Expenses | - | - | 921.87 | 150.94 | 975.62 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.